TriSalus Life Sciences (TLSI) Equity Ratio (2020 - 2026)

TriSalus Life Sciences has reported Equity Ratio for 7 years, with the latest figure at 0.18 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 115.03% year-over-year to 0.18; the trailing twelve-month figure through Mar 2026 stood at 0.18 (up 115.03% YoY), and the FY2025 full-year result was 0.96, up 11.28% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.18, up from 0.96 in the prior quarter.
• The five-year high for Equity Ratio was 0.25 in Q3 2023, with the low at 16.21 in Q2 2023.
• Historically, Equity Ratio has averaged 2.57 across 5 years, with a median of 0.78 in 2024.
• The largest YoY upside for Equity Ratio was 140.35% in 2023 against a maximum downside of 2683.27% in 2023.
• TriSalus Life Sciences' Equity Ratio stood at 8.05 in 2022, then surged by 86.34% to 1.1 in 2023, then rose by 1.82% to 1.08 in 2024, then increased by 11.28% to 0.96 in 2025, then jumped by 118.83% to 0.18 in 2026.
• The last three Equity Ratio figures came in at 0.18 (Q1 2026), 0.96 (Q4 2025), and 0.73 (Q3 2025), per Business Quant data.